Shinpoong Pharmaceutical Co Ltd

Shinpoong Pharmaceutical maintains a strong liquidity position with KRW 47.43 billion in cash and equivalents, but its net cash position is negative after subtracting total debt of KRW 55.86 billion. The company's price-to-book ratio of 2.01 and debt-to-equity ratio of 0.21 indicate a relatively conservative capital structure with limited leverage. The current ratio of 3.09 suggests the company has sufficient short-term assets to cover its liabilities. The company's profitability metrics show a return on equity (ROE) of 3.27% and a return on assets (ROA) of 2.50%, both below the typical thresholds for high-performing pharmaceutical firms. Gross profit of KRW 102.67 billion and operating income of KRW 14.26 billion reflect a gross margin of 43.75% and an operating margin of 6.08%, which are in line with industry norms but not exceptional. Shinpoong Pharmaceutical's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segmental and geographic diversification increases exposure to market-specific risks, particularly in South Korea. The company's revenue growth trajectory is not explicitly provided in the data, but its current FY outlook is neutral with no significant directional guidance. The absence of disclosed capital expenditure plans and a free cash flow of KRW 15.79 billion suggest the company is not currently investing heavily in expansion. The risk assessment indicates a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. The company's ESG controversies score of 100.00 suggests no major controversies, but its governance and social scores of 21.06 and 36.43, respectively, indicate room for improvement in ESG practices. Recent events and filings are not detailed in the provided data, but the company's financial snapshot and risk assessment suggest a stable but unremarkable operational and strategic profile.